205 related articles for article (PubMed ID: 32911199)
21. Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
Ragab FAF; Abou-Seri SM; Abdel-Aziz SA; Alfayomy AM; Aboelmagd M
Eur J Med Chem; 2017 Sep; 138():140-151. PubMed ID: 28667871
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
[TBL] [Abstract][Full Text] [Related]
23. DFT/B3LYP calculations, in vitro cytotoxicity and antioxidant activities of steroidal pyrimidines and their interaction with HSA using molecular docking and multispectroscopic techniques.
Ali A; Asif M; Alam P; Jane Alam M; Asif Sherwani M; Hasan Khan R; Ahmad S; Shamsuzzaman
Bioorg Chem; 2017 Aug; 73():83-99. PubMed ID: 28623723
[TBL] [Abstract][Full Text] [Related]
24. Novel pyrazolo[3,4-d]pyrimidine derivatives inhibit human cancer cell proliferation and induce apoptosis by ROS generation.
Gaonkar S; Savanur MA; Nadaf AA; Najare MS; Mantur S; Garbhagudi M; Mulla SI; Khazi IAM
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900296. PubMed ID: 32073686
[TBL] [Abstract][Full Text] [Related]
25. Novel [1,2,4]triazolo[1,5-a]pyrimidine derivatives as potent antitubulin agents: Design, multicomponent synthesis and antiproliferative activities.
Yang F; Yu LZ; Diao PC; Jian XE; Zhou MF; Jiang CS; You WW; Ma WF; Zhao PL
Bioorg Chem; 2019 Nov; 92():103260. PubMed ID: 31525523
[TBL] [Abstract][Full Text] [Related]
26. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
27. Design and synthesis of novel 1,2,3-triazole-pyrimidine hybrids as potential anticancer agents.
Ma LY; Pang LP; Wang B; Zhang M; Hu B; Xue DQ; Shao KP; Zhang BL; Liu Y; Zhang E; Liu HM
Eur J Med Chem; 2014 Oct; 86():368-80. PubMed ID: 25180925
[TBL] [Abstract][Full Text] [Related]
28. Development of Promising Thiopyrimidine-Based Anti-cancer and Antimicrobial Agents: Synthesis and QSAR Analysis.
Syam YM; Anwar MM; Kotb ER; Elseginy SA; Awad HM; Awad GEA
Mini Rev Med Chem; 2019; 19(15):1255-1275. PubMed ID: 29600761
[TBL] [Abstract][Full Text] [Related]
29. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
[TBL] [Abstract][Full Text] [Related]
30. New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation.
Abdel-Mohsen HT; Girgis AS; Mahmoud AEE; Ali MM; El Diwani HI
Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900089. PubMed ID: 31463965
[TBL] [Abstract][Full Text] [Related]
31. Novel pyrazole-5-carboxamide and pyrazole-pyrimidine derivatives: synthesis and anticancer activity.
Shi JB; Tang WJ; Qi XB; Li R; Liu XH
Eur J Med Chem; 2015 Jan; 90():889-96. PubMed ID: 25554922
[TBL] [Abstract][Full Text] [Related]
32. Pyrrolizine/Indolizine-NSAID Hybrids: Design, Synthesis, Biological Evaluation, and Molecular Docking Studies.
Abourehab MAS; Alqahtani AM; Almalki FA; Zaher DM; Abdalla AN; Gouda AM; Beshr EAM
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770990
[TBL] [Abstract][Full Text] [Related]
33. Novel pyrazolopyrimidines: Synthesis, in vitro cytotoxic activity and mechanistic investigation.
Hassan GS; Abdel Rahman DE; Nissan YM; Abdelmajeed EA; Abdelghany TM
Eur J Med Chem; 2017 Sep; 138():565-576. PubMed ID: 28704759
[TBL] [Abstract][Full Text] [Related]
34. Identification of a promising hit from a new series of pyrazolo[1,5-a]pyrimidine based compounds as a potential anticancer agent with potent CDK1 inhibitory and pro-apoptotic properties through a multistep in vitro assessment.
Elgiushy HR; Mohamed SH; Taha H; Sawaf H; Hassan Z; Abou-Taleb NA; El-Labbad EM; Hassan AS; Abouzid KAM; Hammad SF
Bioorg Chem; 2022 Mar; 120():105646. PubMed ID: 35134645
[TBL] [Abstract][Full Text] [Related]
35. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers.
Abbass EM; Khalil AK; Mohamed MM; Eissa IH; El-Naggar AM
Bioorg Chem; 2020 Nov; 104():104255. PubMed ID: 32927130
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and antiproliferative activity of novel 2,4-diamino-5-methyleneaminopyrimidine derivatives as potential anticancer agents.
Li Q; Chen L; Jian XE; Lv DX; You WW; Zhao PL
Bioorg Med Chem Lett; 2021 Sep; 47():128213. PubMed ID: 34157389
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, Biological Evaluation and Docking Study of New Pyrimidine Compounds as Anticancer Agents.
Boumi S; Moghimirad J; Ostad SN; Amanlou M; Tavajohi S; Amini M
Drug Res (Stuttg); 2021 May; 71(5):284-290. PubMed ID: 33285580
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological evaluation of novel pyrimidine-benzimidazol hybrids as potential anticancer agents.
Shao KP; Zhang XY; Chen PJ; Xue DQ; He P; Ma LY; Zheng JX; Zhang QR; Liu HM
Bioorg Med Chem Lett; 2014 Aug; 24(16):3877-81. PubMed ID: 25001482
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and molecular docking study of new monastrol analogues as kinesin spindle protein inhibitors.
El-Hamamsy MH; Sharafeldin NA; El-Moselhy TF; Tawfik HO
Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000060. PubMed ID: 32452567
[TBL] [Abstract][Full Text] [Related]
40. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation.
Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M
Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
